Tag Archives: Viking Therapeutics

Amgen T2DM Ph3 MariTide H2H vs. Sema Study; Oral VK2735 Ph3 Obesity Program; Ascensia Enters Another CGM Partnership

Three cardiometabolic-related news items have been observed: Amgen registered its Ph3 MARITIME-T2D-3 study evaluating MariTide H2H vs. injectable sema (view CT.gov record); Viking posted its Ph3 SUNRISE obesity program of oral VK2735 (SUNRISE 1 CT.gov record; SUNRISE 2 CT.gov record); and Ascensia entered into a commercial distribution partnership with Sava (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Viking Initiates Oral VK2735 Maintenance Study and the CCO Shares Departure

Two cardiometabolic-related news items have been observed: Viking Therapeutics initiated its Ph1 oral VK2735 maintenance study (view press release), and Viking’s CCO announced his departure via LinkedIn (view post). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Viking Pops 31% on Maintenance Data; Roche Ph2 Enicepatide Results; New Lilly Manufacturing Facility; Obi Approved in the EU; Petrelintide Ph3 Program

A series of cardiometabolic-related news items has been observed from Viking Therapeutics, Roche, Lilly, NewAmsterdam Pharma, and Zealand Pharma. The news items seemingly come hot on the heels of Novo’s obesity-centric Capital Markets Day held Monday. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Viking Ph1 DACRA Study; Lilly Collaborates with Oura; Pivot Patch Pump US Launch; Wave Initiates Ph2a MAD INLIGHT Study; Wegovy FlexTouch Label Update; Tryngolza sHTG US Approval

A series of cardiometabolic-related news items has been observed from Viking Therapeutics, Lilly/Oura, Modular Medical, Wave Life Sciences, Novo Nordisk, and Ionis Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Wave Crashes Following Disappointing Ph1 Obesity Data; Novo’s 2026 Annual General Meeting; Viking Completes VANQUISH-2 Enrollment

Three cardiometabolic-related news items have been observed: Wave Life Sciences announced updated data from its Ph1 INLIGHT study of WVE-007 in obesity (view press release); Novo Nordisk hosted its 2026 Annual General Meeting (view notice); and Viking Therapeutics completed enrollment for its Ph3 VANQUISH-2 study of VK2735 (view press release). Below, FENIX provides highlights and insights from the respective news items.

This content is for Read Less members only.
Already a member? Log in here

JPM 2026 Day 2: LLY, NVO, AMGN, VKTX, AZN, MRK, IONS; Obesity Association Debuts Standards of Care for Obesity Medications

On the second day of JPM 2026, FENIX has provided coverage of presentations by major CVRM companies, including Lilly, Novo Nordisk, Amgen, Viking Therapeutics, AstraZeneca, Merck, and Ionis Pharmaceuticals. Separately, one CVRM-related news item has been observed: The Obesity Association published new standards of care for obesity medications (view press release). Below, FENIX provides insights and highlights for the guidelines.

This content is for Read Less members only.
Already a member? Log in here